[Skip to Navigation]
March 1990

Second Thoughts on 3,4-Methylenedioxymethamphetamine (MDMA) Neurotoxicity-Reply

Author Affiliations

Department of Psychiatry Yale University School of Medicine and the Connecticut Mental Health Center Clinical Neuroscience Research Unit Ribicoff Research Facilities 34 Park St New Haven, CT 06508
Department of Neurology The Johns Hopkins University School of Medicine 4940 Eastern Ave Baltimore, MD 21224

Arch Gen Psychiatry. 1990;47(3):289. doi:10.1001/archpsyc.1990.01810150089015

In Reply.—  Grob et al raise some valid points regarding the methodological limitations of our findings, which we ourselves had attempted to acknowledge, both in the "Comment" section and in our characterization of our results as "preliminary observations." There are, however, several other issues raised by Grob et al on which we offer the following comments:1. Urine toxicology by enzyme immunoassay (EMIT) was obtained on all subjects on the morning of the intravenous L-tryptophan test, immediately prior to beginning the test. Although inadvertently omitted from the final draft of the article, these screens revealed no evidence of recent use of psychoactive drugs. However, most of our subjects did have a past history of use of illicit psychoactive drugs; as Grob et al imply, we cannot state with certainty that use of these other drugs did not account for or contribute to the altered responses to L-tryptophan. The fact is,

Add or change institution